Sho-Ichi Yamagishi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7229750/publications.pdf

Version: 2024-02-01

		6613	10445
379	23,881	79	139
papers	citations	h-index	g-index

379	379	379	20070
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Predictive ability of serum advanced glycation end products at 11 to 13 weeks of gestation for early-onset preeclampsia. AJOG Global Reports, 2022, 2, 100052.	1.0	1
2	Luseogliflozin inhibits high glucose-induced TGF-Î²22 expression in mouse cardiomyocytes by suppressing NHE-1 activity. Journal of International Medical Research, 2022, 50, 030006052210974.	1.0	8
3	Casein Hydrolysate Containing Milk-Derived Peptides Reduces Facial Pigmentation Partly by Decreasing Advanced Glycation End Products in the Skin: A Randomized Double-Blind Placebo-Controlled Trial. Rejuvenation Research, 2021, 24, 97-103.	1.8	3
4	DNA aptamer raised against receptor for advanced glycation end products suppresses renal tubular damage and improves insulin resistance in diabetic mice. Diabetes and Vascular Disease Research, 2021, 18, 147916412199053.	2.0	5
5	Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes. Diabetes Therapy, 2021, 12, 827-842.	2.5	2
6	Pigment epitheliumâ€derived factor inhibits advanced glycation end productâ€induced proliferation, VEGF and MMPâ€9 expression in breast cancer cells via interaction with laminin receptor. Oncology Letters, 2021, 22, 629.	1.8	9
7	Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway. Biomedicines, 2021, 9, 832.	3.2	7
8	DNA-Aptamer Raised against Receptor for Advanced Glycation End Products Improves Survival Rate in Septic Mice. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-20.	4.0	3
9	Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study. Diabetes Research and Clinical Practice, 2021, 179, 108999.	2.8	4
10	Increased Urinary Levels of Pentosidine Measured by a Newly Developed Enzyme-Linked Immunosorbent Assay Are Independently Correlated with Fracture After Fall. Rejuvenation Research, 2021, 24, 449-455.	1.8	0
11	Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-Î²2. Diabetes and Vascular Disease Research, 2021, 18, 147916412199903.	2.0	4
12	Two-hour postload plasma glucose and pigment epithelium-derived factor levels are markers of coronary artery inflammation in type 2 diabetic patients. Journal of Nuclear Cardiology, 2020, 27, 1352-1364.	2.1	5
13	Oral administration of spa-derived green alga improves insulin resistance in overweight subjects: Mechanistic insights from fructose-fed rats. Pharmacological Research, 2020, 152, 104633.	7.1	2
14	Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease. Scientific Reports, 2020, 10, 17647.	3.3	37
15	A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. International Journal of Molecular Sciences, 2020, 21, 4811.	4.1	20
16	AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation. International Journal of Molecular Sciences, 2020, 21, 9263.	4.1	11
17	Butanolic Extract of Noni Inhibits Proliferation, Inflammation, and Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Cultured Smooth Muscle Cells. Natural Product Communications, 2020, 15, 1934578X2093203.	0.5	0
18	Pathological Role of Receptor for Advanced Glycation End Products in Calcified Aortic Valve Stenosis. Journal of the American Heart Association, 2020, 9, e015261.	3.7	12

#	Article	IF	Citations
19	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseaseâ€“A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 1509.	4.1	29
20	Glyceraldehyde-Derived Pyridinium Evokes Renal Tubular Cell Damage via RAGE Interaction. International Journal of Molecular Sciences, 2020, 21, 2604.	4.1	5
21	Brown adipose tissue activation in severe heart failure. European Heart Journal, 2020, 41, 2415-2415.	2.2	3
22	Albuminuriaâ€lowering effect of sodiumâ€glucose cotransporter 2 inhibitors could be partly attributable to the attenuation of tubular damage in type 2 diabetic patients. Diabetes/Metabolism Research and Reviews, 2020, 36, e3327.	4.0	2
23	Fructose causes endothelial cell damage via activation of advanced glycation end productsâ€“receptor system. Diabetes and Vascular Disease Research, 2019, 16, 556-561.	2.0	11
24	Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention. Circulation Journal, 2019, 83, 1822-1828.	1.6	39
25	Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. Bone, 2019, 128, 115034.	2.9	26
26	Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 158, 107904.	2.8	9
27	Long-Term Local Injection of RAGE-Aptamer Suppresses the Growth of Malignant Melanoma in Nude Mice. Journal of Oncology, 2019, 2019, 1-10.	1.3	11
28	Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation. Cardiovascular Diabetology, 2019, 18, 12.	6.8	16
29	Serum Levels of Protein-Bound Methylglyoxal-Derived Hydroimidazolone-1 are Independently Correlated with Asymmetric Dimethylarginine. Rejuvenation Research, 2019, 22, 431-438.	1.8	6
30	Therapeutic Potential of Pigment Epithelium-derived Factor in Cancer. Current Pharmaceutical Design, 2019, 25, 313-324.	1.9	8
31	Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation. Mini-Reviews in Medicinal Chemistry, 2019, 19, 1040-1048.	2.4	9
32	Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Current Vascular Pharmacology, 2019, 17, 411-420.	1.7	22
33	Endothelial dysfunction as a common soil of lower urinary tract symptoms and cardiovascular disease. International Journal of Cardiology, 2018, 261, 209-210.	1.7	1
34	Role of Ligands of Receptor for Advanced Glycation End Products (RAGE) in Peripheral Artery Disease. Rejuvenation Research, 2018, 21, 456-463.	1.8	20
35	RAGE-aptamer attenuates deoxycorticosterone acetate/salt-induced renal injury in mice. Scientific Reports, 2018, 8, 2686.	3.3	24
36	Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population. Journal of International Medical Research, 2018, 46, 1043-1051.	1.0	34

#	Article	IF	Citations
37	Diabetes and Female Sterility/Infertility. , 2018, , 177-183.		3
38	Diabetes and Advanced Glycation End Products. , 2018, , 201-212.		6
39	Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis. Annals of Vascular Diseases, 2018, 11, 253-258.	0.5	48
40	Are Finger Skin Fluorophores Other Than Advanced Glycation End Products (AGEs) Associated With Impaired Musculoskeletal Properties?. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 75, 401-402.	3.6	1
41	Aqueous Extract of Glucoraphanin-Rich Broccoli Sprouts Inhibits Formation of Advanced Glycation End Products and Attenuates Inflammatory Reactions in Endothelial Cells. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-6.	1.2	15
42	Clinical markers associated with glycaemic response to dipeptidyl peptidaseâ€4 inhibitor therapy. Diabetes/Metabolism Research and Reviews, 2018, 34, e3024.	4.0	2
43	An Overview on Diabetic Nephropathy. , 2018, , 125-137.		0
44	Advanced glycation end products evoke inflammatory reactions in proximal tubular cells via autocrine production of dipeptidyl peptidase-4. Microvascular Research, 2018, 120, 90-93.	2.5	18
45	Association of skin autofluorescence with plaque vulnerability evaluated by optical coherence tomography in patients with cardiovascular disease. Atherosclerosis, 2018, 274, 47-53.	0.8	12
46	Sex disparity in cardiovascular mortality rates associated with diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3059.	4.0	3
47	Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications. Current Pharmaceutical Design, 2018, 24, 2802-2809.	1.9	25
48	Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects. International Journal of Food Sciences and Nutrition, 2017, 68, 1013-1020.	2.8	9
49	Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice. Digestive Diseases and Sciences, 2017, 62, 1527-1536.	2.3	21
50	RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy. Diabetes, 2017, 66, 1683-1695.	0.6	91
51	High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 145-154.	4.8	11
52	N-butanol extracts of Morinda citrifolia suppress advanced glycation end products (AGE)-induced inflammatory reactions in endothelial cells through its anti-oxidative properties. BMC Complementary and Alternative Medicine, 2017, 17, 137.	3.7	15
53	Methylglyoxal-derived hydroimidazolone-1 evokes inflammatory reactions in endothelial cells via an interaction with receptor for advanced glycation end products. Diabetes and Vascular Disease Research, 2017, 14, 450-453.	2.0	27
54	Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory. Journal of Diabetes, 2017, 9, 141-148.	1.8	68

#	Article	IF	Citations
55	RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice. Molecular Medicine, 2017, 23, 295-306.	4.4	27
56	Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System. Current Pharmaceutical Design, 2017, 23, 1135-1141.	1.9	19
57	Circulating level of pigment epithelium-derived factor is associated with vascular function and structure: A cross-sectional study. International Journal of Cardiology, 2016, 225, 91-95.	1.7	10
58	Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals. Diabetes and Vascular Disease Research, 2016, 13, 438-441.	2.0	21
59	Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucoseâ€“exposed endothelial cells. Diabetes and Vascular Disease Research, 2016, 13, 312-315.	2.0	7
60	Iridoids are natural glycation inhibitors. Glycoconjugate Journal, 2016, 33, 671-681.	2.7	19
61	DNA-aptamers raised against AGEs as a blocker of various aging-related disorders. Glycoconjugate Journal, 2016, 33, 683-690.	2.7	19
62	Serum Levels of Growth Differentiation Factor 11 Are Independently Associated with Low Hemoglobin Values in Hemodialysis Patients. BioResearch Open Access, 2016, 5, 155-158.	2.6	8
63	Mechanism for the Development of Bone Disease in Diabetes: Increased Oxidative Stress and Advanced Glycation End Products. , 2016, , 63-79.		3
64	Protective role of sulphoraphane against vascular complications in diabetes. Pharmaceutical Biology, 2016, 54, 2329-2339.	2.9	28
65	Protective Role of Sodiumâ€“Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes. Rejuvenation Research, 2016, 19, 107-114.	1.8	10
66	Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention. Nutrition, 2016, 32, 157-165.	2.4	54
67	Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients. Current Vascular Pharmacology, 2016, 14, 552-562.	1.7	21
68	Pigment epithelium-derived factor inhibits caveolin-induced interleukin-8 gene expression and proliferation of human prostate cancer cells. Oncology Letters, 2015, 10, 2644-2648.	1.8	6
69	DNA Aptamer Raised against Advanced Glycation End Products Prevents Abnormalities in Electroretinograms of Experimental Diabetic Retinopathy. Ophthalmic Research, 2015, 54, 175-180.	1.9	11
70	Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetology and Metabolic Syndrome, 2015, 7, 48.	2.7	58
71	Elevation of Serum Levels of Advanced Glycation End Products in Patients With Nonâ€B or Nonâ€C Hepatocellular Carcinoma. Journal of Clinical Laboratory Analysis, 2015, 29, 480-484.	2.1	28
72	Assessment of the Concentrations of Various Advanced Glycation End-Products in Beverages and Foods That Are Commonly Consumed in Japan. PLoS ONE, 2015, 10, e0118652.	2.5	64

#	Article	IF	Citations
73	Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Molecular Medicine, 2015, 21, S32-S40.	4.4	126
74	Receptor for advanced glycation endproducts and progressive kidney disease. Current Opinion in Nephrology and Hypertension, 2015, 24, 54-60.	2.0	38
75	Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is a Predictor of Endothelial Function. Diabetes Care, 2015, 38, 119-125.	8.6	95
76	Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. International Journal of Cardiology, 2015, 184, 14-16.	1.7	4
77	Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system. Thrombosis Research, 2015, 135, 770-773.	1.7	17
78	Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovascular Diabetology, 2015, 14, 2.	6.8	95
79	Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Laboratory Investigation, 2015, 95, 525-533.	3.7	43
80	Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. International Journal of Cardiology, 2015, 185, 263-268.	1.7	85
81	Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE. Cardiovascular Diabetology, 2015, 14, 1.	6.8	87
82	Role of receptor for advanced glycation end products (RAGE) in liver disease. European Journal of Medical Research, 2015, 20, 15.	2.2	49
83	Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia. Neuroscience Letters, 2015, 593, 51-55.	2.1	19
84	Pigment epithelium-derived factor is associated with necrotic core progression during statin therapy. Coronary Artery Disease, 2015, 26, 107-113.	0.7	3
85	Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients. Journal of Cardiovascular Pharmacology, 2015, 65, 289-295.	1.9	65
86	Clinical and Biochemical Factors Associated With Area and Metabolic Activity in the Visceral and Subcutaneous Adipose Tissues by FDG-PET/CT. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E739-E747.	3.6	40
87	Development of a monoclonal antibody-based ELISA system for glyceraldehyde-derived advanced glycation end products. Immunology Letters, 2015, 167, 141-146.	2.5	17
88	Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk. Rejuvenation Research, 2015, 18, 48-56.	1.8	60
89	Oral consumption of sulforaphane precursor-rich broccoli supersprouts decreases serum levels of advanced glycation end products in humans. Diabetes Frontier Online, 2015, 2, 011-011.	0.0	2
90	Involvement of Iron-Evoked Oxidative Stress in Smoking-Related Endothelial Dysfunction in Healthy Young Men. PLoS ONE, 2014, 9, e89433.	2.5	7

#	Article	IF	Citations
91	Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargineâ€injected diabetic patients. Diabetes/Metabolism Research and Reviews, 2014, 30, 693-700.	4.0	19
92	Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system. Thrombosis Research, 2014, 134, 1365-1367.	1.7	19
93	Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovascular Diabetology, 2014, 13, 15.	6.8	28
94	Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World Journal of Hepatology, 2014, 6, 880.	2.0	28
95	Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation. Journal of Leukocyte Biology, 2014, 96, 1077-1085.	3.3	12
96	Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovascular Diabetology, 2014, 13, 60.	6.8	50
97	Change in serum PEDF level after pioglitazone treatment is independently correlated with that in HOMA-IR. International Journal of Cardiology, 2014, 172, 244-246.	1.7	4
98	Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. Clinical and Experimental Medicine, 2014, 14, 45-51.	3.6	2
99	DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. International Journal of Cardiology, 2014, 171, 443-446.	1.7	17
100	Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. International Journal of Cardiology, 2014, 176, 550-552.	1.7	33
101	DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Laboratory Investigation, 2014, 94, 422-429.	3.7	39
102	Dialysate Vascular Endothelial Growth Factor Is an Independent Determinant of Serum Albumin Levels and Predicts Future Withdrawal From Peritoneal Dialysis in Uremic Patients. Therapeutic Apheresis and Dialysis, 2014, 18, 391-397.	0.9	9
103	Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in recurrent pregnancy losses (RPL): possible participation of RAGE in RPL. Fertility and Sterility, 2014, 102, 782-789.	1.0	20
104	Irbesartan inhibits advanced glycation end product-induced increase in asymmetric dimethylarginine level in mesangial cells through its anti-oxidative properties. International Journal of Cardiology, 2014, 176, 1120-1122.	1.7	16
105	Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetology and Metabolic Syndrome, 2014, 6, 86.	2.7	29
106	Sulforaphane inhibits advanced glycation end productâ€“induced pericyte damage by reducing expression of receptor for advanced glycation end products. Nutrition Research, 2014, 34, 807-813.	2.9	26
107	Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of pigment epithelium-derived factor in myeloma cells. Biochemical and Biophysical Research Communications, 2014, 443, 847-851.	2.1	18
108	Pigment Epitheliumâ€“Derived Factor Improves Metabolic Derangements and Ameliorates Dysregulation of Adipocytokines in Obese Type 2 Diabetic Rats. American Journal of Pathology, 2014, 184, 1094-1103.	3.8	22

#	Article	IF	Citations
109	Vascular injury is improved by pre-meal glulisine-based bolus insulin therapy in type 2 diabetic patients. IJC Metabolic & Endocrine, 2014, 4, 70-72.	0.5	0
110	Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris. IJC Metabolic & Endocrine, 2014, 4, 47-52.	0.5	8
111	Sulforaphane inhibits formation of advanced glycation end products in vitro. Diabetes Frontier Online, 2014, 1, 001-001.	0.0	2
112	Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders. Current Pharmaceutical Design, 2014, 20, 2377-2386.	1.9	29
113	Role of AGEs-RAGE System in Cardiovascular Disease. Current Pharmaceutical Design, 2014, 20, 2395-2402.	1.9	143
114	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. Current Pharmaceutical Design, 2014, 20, 2403-2411.	1.9	16
115	Molecular Imaging of Vascular Inflammation. Current Pharmaceutical Design, 2014, 20, 2439-2447.	1.9	13
116	Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome. Current Pharmaceutical Design, 2014, 20, 2448-2455.	1.9	20
117	Minodronate. , 2014, , 2861-2864.		0
118	Minodronate. , 2014, , 1-4.		0
119	DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy. Diabetes, 2013, 62, 3241-3250.	0.6	72
120	Relationship between Advanced Glycation End Products and Plaque Progression in Patients with Acute Coronary Syndrome: The JAPAN-ACS Sub-study. Cardiovascular Diabetology, 2013, 12, 5.	6.8	55
121	Potential Inhibitory Effects of<scp>l</scp>-Carnitine Supplementation on Tissue Advanced Glycation End Products in Patients with Hemodialysis. Rejuvenation Research, 2013, 16, 460-466.	1.8	27
122	Efficacy of alogliptin, a dipeptidyl peptidaseâ€4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) â€“ receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 624-630.	4.0	59
123	Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF. International Journal of Cardiology, 2013, 167, 3072-3074.	1.7	2
124	Evidence for a Positive Association Between Serum Carnitine and Free Testosterone Levels in Uremic Men with Hemodialysis. Rejuvenation Research, 2013, 16, 200-205.	1.8	3
125	Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells. Microvascular Research, 2013, 90, 64-70.	2.5	37
126	Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovascular Diabetology, 2013, 12, 125.	6.8	142

#	Article	IF	Citations
127	Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4438-4445.	3.6	39
128	sRAGE is associated with low waist circumference and Hb levels in NAFLD. Open Medicine (Poland), 2013, 8, 830-834.	1.3	0
129	Pigment epithelium-derived factor (PEDF) binds to caveolin-1 and inhibits the pro-inflammatory effects of caveolin-1 in endothelial cells. Biochemical and Biophysical Research Communications, 2013, 441, 405-410.	2.1	18
130	Rosuvastatin restores advanced glycation end product-induced decrease in sirtuin1 (SIRT1) mRNA levels in THP-1 monocytic cells through its anti-oxidative properties. International Journal of Cardiology, 2013, 169, e102-e103.	1.7	4
131	Pigment epithelium-derived factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties. Biochemical and Biophysical Research Communications, 2013, 431, 693-697.	2.1	21
132	Pigment epithelium-derived factor (PEDF) blocks high glucose-induced inflammatory reactions in endothelial cells through its anti-oxidative properties. International Journal of Cardiology, 2013, 168, 3004-3006.	1.7	8
133	Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clinical Biochemistry, 2013, 46, 300-303.	1.9	35
134	Pioglitazone Decreases Asymmetric Dimethylarginine Levels in Patients with Impaired Glucose Tolerance or Type 2 Diabetes. Rejuvenation Research, 2013, 16, 344-351.	1.8	12
135	Telmisartan inhibits AGE-induced podocyte damage and detachment. Microvascular Research, 2013, 88, 79-83.	2.5	21
136	Author reply: Comment to â€œAtorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-Î±-lowering propertyâ€. Digestive and Liver Disease, 2013, 45, 82.	0.9	0
137	Author reply: Comment to â€œAtorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-Î±-lowering propertyâ€. Digestive and Liver Disease, 2013, 45, 83-84.	0.9	0
138	Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Productâ€“Induced Protein Arginine Methyltranferase-1 Expression. American Journal of Pathology, 2013, 182, 132-141.	3.8	125
139	PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation. Microvascular Research, 2013, 85, 54-58.	2.5	48
140	Comment on: Selvin et al. sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death. Diabetes 2013;62:2116-2121. Diabetes, 2013, 62, e26-e26.	0.6	6
141	Beneficial Effects of Vildagliptin on Retinal Injury in Obese Type 2 Diabetic Rats. Ophthalmic Research, 2013, 50, 221-226.	1.9	21
142	Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diabetes and Vascular Disease Research, 2013, 10, 436-441.	2.0	55
143	Sodiumâ€glucose cotransporter 2â€mediated oxidative stress augments advanced glycation end productsâ€induced tubular cell apoptosis. Diabetes/Metabolism Research and Reviews, 2013, 29, 406-412.	4.0	73
144	Pigment Epitheliumâ€Derived Factor as a New Predictor of Mortality Among Chronic Kidney Disease Patients Treated With Hemodialysis. Therapeutic Apheresis and Dialysis, 2013, 17, 625-630.	0.9	4

#	Article	IF	Citations
145	A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2013, 13, 81-88.	0.5	2
146	Comment on: Monami et al. Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials. Diabetes Care 2011;34:2474-2476. Diabetes Care, 2012, 35, e33-e33.	8.6	3
147	Positive Association Between Serum Level of Glyceraldehyde-Derived Advanced Glycation End Products and Vascular Inflammation Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomography. Diabetes Care, 2012, 35, 2618-2625.	8.6	78
148	Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 122-127.	1.7	16
149	An Overview of Diabetic Nephropathy. , 2012, , 145-157.		2
150	Serum Levels of Advanced Glycation End Products (AGEs) are Independent Correlates of Insulin Resistance in Nondiabetic Subjects. Cardiovascular Therapeutics, 2012, 30, 42-48.	2.5	96
151	Serum Levels of Advanced Glycation End Products (AGEs) are Inversely Associated with the Number and Migratory Activity of Circulating Endothelial Progenitor Cells in Apparently Healthy Subjects. Cardiovascular Therapeutics, 2012, 30, 249-254.	2.5	42
152	Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology, 2012, 17, 689-694.	1.6	20
153	Potential Clinical Utility of Advanced Glycation End Product Cross-Link Breakers in Age- and Diabetes-Associated Disorders. Rejuvenation Research, 2012, 15, 564-572.	1.8	57
154	Serum levels of pigment epithelium-derived factor, a novel marker of insulin resistance, are independently associated with fasting apolipoprotein B48 levels in humans. Clinical Biochemistry, 2012, 45, 1404-1408.	1.9	7
155	Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease. Clinical Biochemistry, 2012, 45, 1554-1557.	1.9	4
156	Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism: Clinical and Experimental, 2012, 61, 1067-1072.	3.4	66
157	Advanced Glycation End Products Increase Permeability of Brain Microvascular Endothelial Cells through Reactive Oxygen Speciesâ€"Induced Vascular Endothelial Growth Factor Expression. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 293-298.	1.6	31
158	PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression. Microvascular Research, 2012, 84, 105-108.	2.5	39
159	Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy. International Journal of Cardiology, 2012, 155, 294-296.	1.7	6
160	Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. International Journal of Cardiology, 2012, 158, 171-173.	1.7	29
161	Serum pigment epithelium-derived factor levels are independently associated with decreased number of circulating endothelial progenitor cells in healthy non-smokers. International Journal of Cardiology, 2012, 158, 310-312.	1.7	2
162	Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation. International Journal of Cardiology, 2012, 158, 461-462.	1.7	32

#	Article	IF	Citations
163	Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 663-671.	2.4	226
164	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-Î±-lowering property. Digestive and Liver Disease, 2012, 44, 492-496.	0.9	50
165	Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. Digestive and Liver Disease, 2012, 44, 935-939.	0.9	4
166	Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)â€“RAGE-induced proximal tubular cell injury. Pharmacological Research, 2012, 65, 297-302.	7.1	39
167	Proteinuria elevates asymmetric dimethylarginine levels via protein arginine methyltransferase-1 overexpression in a rat model of nephrotic syndrome. Life Sciences, 2012, 91, 301-305.	4.3	13
168	Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvascular Research, 2012, 84, 395-398.	2.5	38
169	Statins and hemoperfusion improve 28-day survival in septic shock patients. Open Medicine (Poland), 2012, 7, 475-480.	1.3	0
170	Pioglitazone Attenuates Atherosclerotic Plaque Inflammation in Patients With Impaired Glucose Tolerance or Diabetes. JACC: Cardiovascular Imaging, 2011, 4, 1110-1118.	5.3	126
171	Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacological Research, 2011, 63, 241-248.	7.1	50
172	Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end productâ€“receptor axis. Pharmacological Research, 2011, 63, 383-388.	7.1	88
173	Administration of Pigment Epithelium-Derived Factor Inhibits Left Ventricular Remodeling and Improves Cardiac Function in Rats with Acute Myocardial Infarction. American Journal of Pathology, 2011, 178, 591-598.	3.8	41
174	Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvascular Research, 2011, 81, 269-273.	2.5	20
175	Osteogenic differentiation of mesenchymal stem cells is preserved by partial, but not full peroxisome proliferator-activated receptor-gamma agonist. International Journal of Cardiology, 2011, 146, 109-110.	1.7	1
176	Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property. International Journal of Cardiology, 2011, 146, 264-266.	1.7	7
177	Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. International Journal of Cardiology, 2011, 146, 420-421.	1.7	9
178	Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. International Journal of Cardiology, 2011, 152, 408-410.	1.7	29
179	Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathyâ€”Friend or foe?. Pharmacological Research, 2011, 64, 187-194.	7.1	100
180	Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis, 2011, 219, 311-315.	0.8	48

#	Article	IF	Citations
181	Activation of Receptor for Advanced Glycation End Products Induces Osteogenic Differentiation of Vascular Smooth Muscle Cells. Journal of Atherosclerosis and Thrombosis, 2011, 18, 670-683.	2.0	72
182	Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes. Current Pharmaceutical Design, 2011, 17, 4379-4385.	1.9	35
183	Association between Plasma Pigment Epithelium-derived Factor Levels and Tissue Characteristics of Coronary Plaque using Integrated Backscatter Intravascular Ultrasound. Internal Medicine, 2011, 50, 1889-1894.	0.7	5
184	Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes. Current Drug Targets, 2011, 12, 2096-2102.	2.1	127
185	Tissue level of advanced glycation end products is an independent determinant of highâ€sensitivity Câ€reactive protein levels in haemodialysis patients. Nephrology, 2011, 16, 299-303.	1.6	21
186	Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation. Metabolism: Clinical and Experimental, 2011, 60, 260-264.	3.4	44
187	Glucagon-like peptideâ€“1 suppresses advanced glycation end productâ€“induced monocyte chemoattractant proteinâ€“1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism: Clinical and Experimental, 2011, 60, 1271-1277.	3.4	86
188	Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin Bâ€“immobilized fiber hemoperfusion in septic shock patients. Journal of Critical Care, 2011, 26, 546-549.	2.2	13
189	Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Experimental Gerontology, 2011, 46, 217-224.	2.8	231
190	High White Blood Cell Count and Low Estimated Glomerular Filtration Rate Are Independently Associated With Serum Level of Monocyte Chemoattractant Proteinâ€1 in a General Population. Clinical Cardiology, 2011, 34, 189-194.	1.8	15
191	Beneficial Cardiometabolic Actions of Telmisartan Plus Amlodipine Therapy in Elderly Patients With Poorly Controlled Hypertension. Clinical Cardiology, 2011, 34, 261-265.	1.8	7
192	Calcium Channel Blocker Inhibition of AGE and RAGE Axis Limits Renal Injury in Nondiabetic Patients With Stage I or II Chronic Kidney Disease. Clinical Cardiology, 2011, 34, 372-377.	1.8	23
193	Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clinical and Experimental Medicine, 2011, 11, 131-135.	3.6	19
194	Involvement of membrane type 1â€matrix metalloproteinase (MT1â€MMP) in RAGE activation signaling pathways. Journal of Cellular Physiology, 2011, 226, 1554-1563.	4.1	22
195	Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group boxÂ1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clinical Biochemistry, 2011, 44, 601-604.	1.9	70
196	Significance of pigment epithelium-derived factor levels with angiotensin II type 1 receptor blockers in patients with successful coronary stent implantation. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 320-325.	1.7	1
197	Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy. Current Pharmaceutical Biotechnology, 2011, 12, 362-368.	1.6	66
198	Minodronate. , 2011, , 2325-2327.		0

#	Article	IF	Citations
199	Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, e58-e58.	8.6	2
200	The p66^{shc} Gene Expression in Peripheral Blood Monocytes Is Increased in Patients With Coronary Artery Disease. Clinical Cardiology, 2010, 33, 548-552.	1.8	16
201	An Î±-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clinical and Experimental Medicine, 2010, 10, 139-141.	3.6	29
202	Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. Journal of Gastroenterology, 2010, 45, 750-757.	5.1	141
203	Immunological detection of fructose-derived advanced glycation end-products. Laboratory Investigation, 2010, 90, 1117-1127.	3.7	49
204	Atorvastatin Reduces Proteinuria in Non-Diabetic Chronic Kidney Disease Patients Partly via Lowering Serum Levels of Advanced Glycation End Products (AGEs). Oxidative Medicine and Cellular Longevity, 2010, 3, 304-307.	4.0	26
205	Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy. Oxidative Medicine and Cellular Longevity, 2010, 3, 101-108.	4.0	298
206	Efficacy of Combination Therapy with Telmisartan Plus Amlodipine in Patients with Poorly Controlled Hypertension. Oxidative Medicine and Cellular Longevity, 2010, 3, 342-346.	4.0	6
207	Soluble form of a receptor for advanced glycation end products sRAGE as a biomarker. Frontiers in Bioscience - Elite, 2010, E2, 1184-1195.	1.8	114
208	Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. Journal of Ophthalmology, 2010, 2010, 1-12.	1.3	18
209	Cancer Malignancy Is Enhanced by Glyceraldehyde-Derived Advanced Glycation End-Products. Journal of Oncology, 2010, 2010, 1-8.	1.3	51
210	Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy. Current Drug Targets, 2010, 11, 1468-1482.	2.1	81
211	Insulin Resistance is an Independent Correlate of High Serum Levels of Advanced Glycation End Products (AGEs) and Low Testosterone in Non-Diabetic Men. Oxidative Medicine and Cellular Longevity, 2010, 3, 262-265.	4.0	18
212	An improved anion-exchange high-performance liquid chromatography method for measuring oxidized form of LDLs in human plasma. Annals of Clinical Biochemistry, 2010, 47, 460-466.	1.6	2
213	Irbesartan Inhibits Albumin-Elicited Proximal Tubular Cell Apoptosis and Injury In Vitro. Protein and Peptide Letters, 2010, 17, 74-77.	0.9	12
214	Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs). Current Drug Targets, 2010, 11, 875-881.	2.1	24
215	Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice. Protein and Peptide Letters, 2010, 17, 1177-1181.	0.9	45
216	Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis. Journal of Dermatological Science, 2010, 57, 183-191.	1.9	33

#	Article	IF	Citations
217	Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacological Research, 2010, 61, 103-107.	7.1	31
218	Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacological Research, 2010, 61, 34-39.	7.1	62
219	Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacological Research, 2010, 61, 58-61.	7.1	42
220	Involvement of angiotensin II in intestinal cholesterol absorption. Pharmacological Research, 2010, 61, 460-465.	7.1	8
221	Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-Î¹B activation. Microvascular Research, 2010, 80, 227-232.	2.5	51
222	Pigment epithelium-derived factor (PEDF) inhibits collagen-induced platelet activation by reducing intraplatelet nitrotyrosine levels. International Journal of Cardiology, 2010, 140, 121-122.	1.7	9
223	Serum levels of pigment epithelium-derived factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. International Journal of Cardiology, 2010, 143, 96-98.	1.7	30
224	Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats. International Journal of Cardiology, 2010, 144, 283-285.	1.7	4
225	Involvement of aldosterone-mineralocorticoid receptor system in advanced glycation end product (AGE)-elicited plasminogen activator inhibitor-1 (PAI-1) expression in diabetes. International Journal of Cardiology, 2010, 145, 566-567.	1.7	3
226	Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochemical and Biophysical Research Communications, 2010, 391, 1405-1408.	2.1	136
227	Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochemical and Biophysical Research Communications, 2010, 396, 566-570.	2.1	27
228	Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochemical and Biophysical Research Communications, 2010, 398, 326-330.	2.1	33
229	Pigment Epithelium-Derived Factor Inhibits Lysosomal Degradation of Bcl-xL and Apoptosis in HepG2 cells. American Journal of Pathology, 2010, 176, 168-176.	3.8	21
230	Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrology Dialysis Transplantation, 2009, 24, 1397-1406.	0.7	33
231	Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism: Clinical and Experimental, 2009, 58, 421-425.	3.4	19
232	Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism: Clinical and Experimental, 2009, 58, 1688-1693.	3.4	43
233	Protective role of pigment epitheliumâ€derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes/Metabolism Research and Reviews, 2009, 25, 678-686.	4.0	103
234	Serum levels of pigment epitheliumâ€derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2009, 25, 52-56.	4.0	61

#	Article	IF	Citations
235	Pigment epitheliumâ€derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes/Metabolism Research and Reviews, 2009, 25, 266-271.	4.0	41
236	Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys. European Journal of Nutrition, 2009, 48, 6-11.	3.9	33
237	Advanced Glycation End Products and Receptorâ€“Oxidative Stress System in Diabetic Vascular Complications. Therapeutic Apheresis and Dialysis, 2009, 13, 534-539.	0.9	53
238	Decreased Highâ€Density Lipoprotein Cholesterol Level is an Independent Correlate of Circulating Tumor Necrosis Factorâ€± in a General Population. Clinical Cardiology, 2009, 32, E29-32.	1.8	15
239	Lowâ€Density Lipoprotein Levels are One of the Independent Determinants of Circulating Levels of Advanced Glycation End Products in Nondiabetic Subjects. Clinical Cardiology, 2009, 32, E12-5.	1.8	8
240	Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochemical and Biophysical Research Communications, 2009, 385, 269-272.	2.1	48
241	Serum level of pigment epithelium derived factor (PEDF) is an independent determinant of resting heart rate in Japanese subjects. International Journal of Cardiology, 2009, 136, 245-247.	1.7	13
242	Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. Pharmacological Research, 2009, 60, 174-178.	7.1	67
243	Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacological Research, 2009, 60, 525-528.	7.1	44
244	Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacological Research, 2009, 60, 515-518.	7.1	41
245	Positive association of serum levels of advanced glycation end products and high mobility group boxâ€“1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism: Clinical and Experimental, 2009, 58, 1624-1628.	3.4	48
246	Involvement of Toxic AGEs (TAGE) in the Pathogenesis of Diabetic Vascular Complications and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 845-858.	2.6	104
247	Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders. Current Drug Metabolism, 2009, 10, 159-163.	1.2	41
248	Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders. Current Pharmaceutical Design, 2009, 15, 1027-1033.	1.9	47
249	Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. Journal of Gastroenterology, 2008, 43, 298-304.	5.1	93
250	Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant proteinâ€1 (MCPâ€1) levels in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2008, 24, 109-114.	4.0	80
251	Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2â€deficient mice. Genes To Cells, 2008, 13, 1159-1170.	1.2	175
252	Inhibitors of Advanced Glycation End Products (AGEs): Potential Utility for the Treatment of Cardiovascular Disease. Cardiovascular Drug Reviews, 2008, 26, 50-58.	4.1	23

#	Article	IF	Citations
253	Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvascular Research, 2008, 75, 130-134.	2.5	56
254	Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvascular Research, 2008, 76, 52-56.	2.5	87
255	Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis, 2008, 197, 25-33.	0.8	49
256	Role of AGEs in Diabetic Nephropathy. Current Pharmaceutical Design, 2008, 14, 946-952.	1.9	127
257	Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications. Current Pharmaceutical Design, 2008, 14, 2613-2618.	1.9	38
258	Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs, 2008, 17, 983-996.	4.1	121
259	Olmesartan Blocks Inflammatory Reactions in Endothelial Cells Evoked by Advanced Glycation End Products by Suppressing Generation of Reactive Oxygen Species. Ophthalmic Research, 2008, 40, 10-15.	1.9	59
260	Role of Oxidative Stress in the Development of Vascular Injury and its Therapeutic Intervention by Nifedipine. Current Medicinal Chemistry, 2008, 15, 172-177.	2.4	50
261	Receptor for Advanced Glycation End Products (RAGE): A Novel Therapeutic Target for Diabetic Vascular Complication. Current Pharmaceutical Design, 2008, 14, 487-495.	1.9	95
262	AGE-RAGE System and Carcinogenesis. Current Pharmaceutical Design, 2008, 14, 940-945.	1.9	149
263	Advanced Glycation End Products and Insulin Resistance. Current Pharmaceutical Design, 2008, 14, 987-989.	1.9	142
264	Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Diabetic Retinopathy. Current Pharmaceutical Design, 2008, 14, 962-968.	1.9	89
265	Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease. Current Pharmaceutical Design, 2008, 14, 969-972.	1.9	123
266	Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimers Disease. Current Pharmaceutical Design, 2008, 14, 973-978.	1.9	200
267	Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA. European Heart Journal, 2008, 29, 1922-1922.	2.2	3
268	Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. Nephrology Dialysis Transplantation, 2008, 24, 1162-1169.	0.7	48
269	Comment on: Thallas-Bonke et al. (2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-Â-Dependent Pathway: Diabetes 57:460-469, 2008. Diabetes, 2008, 57, e13-e13.	0.6	5
270	Telmisartan Inhibits Advanced Glycation End Products (AGEs)-Elicited Endothelial Cell Injury by Suppressing AGE Receptor (RAGE) Expression Via Peroxisome Proliferator-Activated Receptor-γ Activation. Protein and Peptide Letters, 2008, 15, 850-853.	0.9	43

#	Article	IF	Citations
271	Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition. Current Pharmaceutical Design, 2008, 14, 3802-3809.	1.9	17
272	Pigment Epithelium-Derived Factor (PEDF): Its Potential Therapeutic Implication in Diabetic Vascular Complications. Current Drug Targets, 2008, 9, 1025-1029.	2.1	40
273	Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ). Letters in Drug Design and Discovery, 2008, 5, 477-480.	0.7	6
274	Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. British Journal of Ophthalmology, 2007, 91, 885-887.	3.9	38
275	Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma. Mini-Reviews in Medicinal Chemistry, 2007, 7, 649-661.	2.4	25
276	Pigment Epithelium-Derived Factor (PEDF) Prevents Advanced Glycation End Products (AGEs)-Elicited Endothelial Nitric Oxide Synthase (eNOS) Reduction Through Its Anti-Oxidative Properties. Protein and Peptide Letters, 2007, 14, 832-835.	0.9	35
277	Potential Utility of Telmisartan, an Angiotensin II Type 1 Receptor Blocker with Peroxisome Proliferator-Activated Receptor-Î³ (PPAR-Î³)-Modulating Activity for the Treatment of Cardiometabolic Disorders. Current Molecular Medicine, 2007, 7, 463-469.	1.3	72
278	Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders. Current Pharmaceutical Design, 2007, 13, 2832-2836.	1.9	114
279	Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy. British Journal of Ophthalmology, 2007, 91, 1133-1134.	3.9	22
280	Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis. British Journal of Ophthalmology, 2007, 91, 737-738.	3.9	11
281	Pigment-Epithelium-Derived Factor Suppresses Expression of Receptor for Advanced Glycation End Products in the Eye of Diabetic Rats. Ophthalmic Research, 2007, 39, 92-97.	1.9	53
282	Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention. Current Drug Targets, 2007, 8, 952-959.	2.1	137
283	Serum Levels of Soluble Form of Receptor for Advanced Glycation End Products (sRAGE) May Reflect Tissue RAGE Expression In Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, e32; author reply e33-4.	2.4	30
284	Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1525-1533.	6.1	106
285	Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. British Journal of Ophthalmology, 2007, 91, 397-398.	3.9	14
286	Fluvastatin Alters Platelet Aggregability in Patients With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1471-1477.	2.4	65
287	Kinetics, Role and Therapeutic Implications of Endogenous Soluble form of Receptor for Advanced Glycation end Products (sRAGE) in Diabetes. Current Drug Targets, 2007, 8, 1138-1143.	2.1	71
288	Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 236-240.	1.0	28

#	Article	IF	Citations
289	Pigment Epithelium-Derived Factor (PEDF) Inhibits Angiotensin IIInduced Smooth Muscle Cell Proliferation Through Its Anti-Oxidative Properties. Protein and Peptide Letters, 2007, 14, 615-617.	0.9	10
290	Signal Transduction Therapy of Diabetic Vascular Complication. Current Signal Transduction Therapy, 2007, 2, 91-100.	0.5	5
291	Upregulation of the ligandâ€“RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. Journal of Molecular and Cellular Cardiology, 2007, 43, 455-464.	1.9	37
292	Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Research and Clinical Practice, 2007, 76, 236-244.	2.8	135
293	Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimerâ€™s disease. Medical Hypotheses, 2007, 69, 1358-1366.	1.5	39
294	In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes. Microvascular Research, 2007, 74, 65-69.	2.5	25
295	Elevated circulating oxidized LDL levels in Japanese subjects with the metabolic syndrome. International Journal of Cardiology, 2007, 118, 270-272.	1.7	21
296	Pigment Epithelium-Derived Factor Inhibits Neointimal Hyperplasia after Vascular Injury by Blocking NADPH Oxidase-Mediated Reactive Oxygen Species Generation. American Journal of Pathology, 2007, 170, 2159-2170.	3.8	66
297	Vascular Inflammation Evaluated by [18F]-Fluorodeoxyglucose Positron Emission Tomography Is Associated With the Metabolic Syndrome. Journal of the American College of Cardiology, 2007, 49, 1533-1539.	2.8	226
298	Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes. Molecular Medicine, 2007, 13, 185-189.	4.4	125
299	Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes/Metabolism Research and Reviews, 2007, 23, 368-371.	4.0	124
300	Elevated levels of serum advanced glycation end products in patients with nonâ€alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1112-1119.	2.8	164
301	Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease (Review Article). Nephrology, 2007, 12, 582-590.	1.6	61
302	Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Research, 2007, 1167, 92-100.	2.2	25
303	Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascular Pharmacology, 2007, 46, 286-292.	2.1	53
304	Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clinical and Experimental Nephrology, 2007, 11, 115-121.	1.6	51
305	Increased levels of pigment epithelium-derived factor in aqueous humor of patients with uveitis. British Journal of Ophthalmology, 2007, 91, 149-150.	3.9	13
306	Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation. Vascular Disease Prevention, 2007, 4, 213-216.	0.2	2

#	Article	IF	Citations
307	Elevated Serum Levels of Pigment Epithelium-Derived Factor in the Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2447-2450.	3.6	182
308	Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism: Clinical and Experimental, 2006, 55, 912-917.	3.4	40
309	Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism: Clinical and Experimental, 2006, 55, 1227-1231.	3.4	137
310	Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Letters, 2006, 580, 2788-2796.	2.8	33
311	Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation. Life Sciences, 2006, 79, 1981-1987.	4.3	12
312	Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvascular Research, 2006, 71, 222-226.	2.5	23
313	Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvascular Research, 2006, 72, 86-90.	2.5	77
314	Oral Adsorbent AST-120 Decreases Serum Levels of AGEs in Patients with Chronic Renal Failure. Molecular Medicine, 2006, 12, 180-184.	4.4	54
315	Pigment Epithelium-Derived Factor (PEDF) Blocks Angiotensin IIInduced T Cell Proliferation by Suppressing Autocrine Production of Interleukin-2. Medicinal Chemistry, 2006, 2, 265-269.	1.5	13
316	Low-Density Lipoprotein Subfractions and the Prevalence of Silent Lacunar Infarction in Subjects with Essential Hypertension. Hypertension Research, 2006, 29, 303-307.	2.7	15
317	Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species. Brain Research, 2006, 1108, 179-187.	2.2	40
318	Advanced glycation end-products downregulating intervertebral disc cell production of proteoglycans in vitro. Journal of Neurosurgery: Spine, 2006, 5, 324-329.	1.7	26
319	Telmisartan, its Potential Therapeutic Implications in Cardiometabolic Disorders. Recent Patents on Cardiovascular Drug Discovery, 2006, 1, 79-83.	1.5	2
320	Cardiovascular Disease in Diabetes. Mini-Reviews in Medicinal Chemistry, 2006, 6, 313-318.	2.4	19
321	Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy. Current Drug Discovery Technologies, 2006, 3, 83-88.	1.2	38
322	Circulating Oxidized Low-density Lipoprotein (LDL) Induces Apoptosis and Stimulates Monocyte Chemoattractant Protein-1 Expression in Cultured Endothelial Cells. Letters in Drug Design and Discovery, 2006, 3, 582-585.	0.7	1
323	Atorvastatin and Diabetic Vascular Complications. Current Pharmaceutical Design, 2006, 12, 1549-1554.	1.9	32
324	Pleiotropic Effects of Nifedipine on Atherosclerosis. Current Pharmaceutical Design, 2006, 12, 1543-1547.	1.9	27

#	Article	IF	Citations
325	TAGE (Toxic AGEs) Theory in Diabetic Complications. Current Molecular Medicine, 2006, 6, 351-358.	1.3	174
326	Molecular Mechanism for Elevation of Asymmetric Dimethylarginine and Its Role for Hypertension in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2006, 17, 2176-2183.	6.1	153
327	Increased Serum Concentrations of Pigment Epithelium-Derived Factor in Patients with End-Stage Renal Disease. Clinical Chemistry, 2006, 52, 1970-1971.	3.2	31
328	Role of Advanced Glycation End Products (AGEs) in Thrombogenic Abnormalities in Diabetes. Current Neurovascular Research, 2006, 3, 73-77.	1.1	74
329	Toxic Advanced Glycation End Products (TAGE) Theory in Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 197-208.	1.9	115
330	Pigment Epithelium-derived Factor Inhibits Advanced Glycation End Product-induced Retinal Vascular Hyperpermeability by Blocking Reactive Oxygen Species-mediated Vascular Endothelial Growth Factor Expression. Journal of Biological Chemistry, 2006, 281, 20213-20220.	3.4	194
331	Advanced Glycation End-Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone. Journal of Bone and Mineral Research, 2005, 20, 1647-1658.	2.8	245
332	Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell and Tissue Research, 2005, 320, 437-445.	2.9	108
333	Diabetic Vascular Complications: Pathophysiology, Biochemical Basis and Potential Therapeutic Strategy. Current Pharmaceutical Design, 2005, 11, 2279-2299.	1.9	432
334	Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications. Current Diabetes Reviews, 2005, 1, 93-106.	1.3	141
335	Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvascular Research, 2005, 69, 45-55.	2.5	75
336	Pigment epithelium-derived factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B. Microvascular Research, 2005, 69, 128-134.	2.5	18
337	Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvascular Research, 2005, 70, 137-141.	2.5	107
338	Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sciences, 2005, 77, 3231-3241.	4.3	91
339	Angiotensin II augments advanced glycation end productâ€induced pericyte apoptosis through RAGE overexpression. FEBS Letters, 2005, 579, 4265-4270.	2.8	66
340	Therapeutic Implications of Blockers of Advanced Glycation End Products (AGEs)-their Receptor (RAGE) System. International Journal of Pharmacology, 2005, 1, 203-209.	0.3	3
341	Involvement of Advanced Glycation End-products (AGEs) in Alzheimers Disease. Current Alzheimer Research, 2004, 1, 39-46.	1.4	116
342	Azelnidipine, A Newly Developed Long-Acting Calcium Antagonist, Inhibits Tumor Necrosis Factor-Î±-Induced Interleukin-8 Expression in Endothelial Cells through its Anti-Oxidative Properties. Journal of Cardiovascular Pharmacology, 2004, 43, 724-730.	1.9	68

#	Article	IF	Citations
343	AGEs activate mesangial TGF-Î²â€“Smad signaling via an angiotensin II type I receptor interaction. Kidney International, 2004, 66, 2137-2147.	5.2	198
344	AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes. Journal of Diabetes and Its Complications, 2004, 18, 53-59.	2.3	22
345	Regulation of Human Melanoma Growth and Metastasis by AGEâ€“AGE Receptor Interactions. Journal of Investigative Dermatology, 2004, 122, 461-467.	0.7	130
346	Pigment epithelium-derived factor inhibits TNF-Î±-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. Journal of Molecular and Cellular Cardiology, 2004, 37, 497-506.	1.9	128
347	Overexpression of Pigment Epithelium-Derived Factor Decreases Angiogenesis and Inhibits the Growth of Human Malignant Melanoma Cells in Vivo. American Journal of Pathology, 2004, 164, 1225-1232.	3.8	119
348	Minodronate, a Newly Developed Nitrogen-Containing Bisphosphonate, Suppresses Melanoma Growth and Improves Survival in Nude Mice by Blocking Vascular Endothelial Growth Factor Signaling. American Journal of Pathology, 2004, 165, 1865-1874.	3.8	82
349	Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. Journal of Diabetes and Its Complications, 2003, 17, 16-21.	2.3	125
350	Advanced glycation end products inhibit de novo protein synthesis and induce TGF-Î² overexpression in proximal tubular cells. Kidney International, 2003, 63, 464-473.	5.2	140
351	Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvascular Research, 2003, 65, 186-190.	2.5	97
352	Neurotoxicity of Acetaldehyde-Derived Advanced Glycation End Products for Cultured Cortical Neurons. Journal of Neuropathology and Experimental Neurology, 2003, 62, 486-496.	1.7	32
353	Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB Journal, 2002, 16, 1928-1930.	0.5	247
354	Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells. Journal of Biological Chemistry, 2002, 277, 20309-20315.	3.4	275
355	Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal Pericytes. Biochemical and Biophysical Research Communications, 2002, 290, 973-978.	2.1	204
356	Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochemical and Biophysical Research Communications, 2002, 296, 877-882.	2.1	178
357	Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochemical and Biophysical Research Communications, 2002, 297, 419-424.	2.1	55
358	Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochemical and Biophysical Research Communications, 2002, 299, 183-188.	2.1	56
359	Interferon-Î³-induced apoptosis and activation of THP-1 macrophages. Life Sciences, 2002, 71, 2499-2508.	4.3	35
360	Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques.. Neuroscience Letters, 2002, 326, 117-120.	2.1	97

#	Article	IF	Citations
361	Palmitate-Induced Apoptosis of Microvascular Endothelial Cells and Pericytes. Molecular Medicine, 2002, 8, 179-184.	4.4	71
362	CS-866, a New Angiotensin II Type 1 Receptor Antagonist, Ameliorates Glomerular Anionic Site Loss and Prevents Progression of Diabetic Nephropathy in Otsuka Long-Evans Tokushima Fatty Rats. Molecular Medicine, 2002, 8, 591-599.	4.4	23
363	Beraprost Sodium, a Prostaglandin I2 Analogue, Protects Against Advanced Glycation End Products-induced Injury in Cultured Retinal Pericytes. Molecular Medicine, 2002, 8, 546-550.	4.4	52
364	Palmitate-induced apoptosis of microvascular endothelial cells and pericytes. Molecular Medicine, 2002, 8, 179-84.	4.4	24
365	Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Molecular Medicine, 2002, 8, 546-50.	4.4	13
366	Immunological Detection of a Novel Advanced Glycation End-Product. Molecular Medicine, 2001, 7, 783-791.	4.4	85
367	Leptin Induces Mitochondrial Superoxide Production and Monocyte Chemoattractant Protein-1 Expression in Aortic Endothelial Cells by Increasing Fatty Acid Oxidation via Protein Kinase A. Journal of Biological Chemistry, 2001, 276, 25096-25100.	3.4	530
368	Hyperglycemia Potentiates Collagen-Induced Platelet Activation Through Mitochondrial Superoxide Overproduction. Diabetes, 2001, 50, 1491-1494.	0.6	199
369	Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. Journal of Clinical Investigation, 2001, 108, 261-268.	8.2	430
370	Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404, 787-790.	27.8	3,895
371	Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clinical Pharmacology and Therapeutics, 2000, 67, 57-69.	4.7	101
372	The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-Î± through Nuclear Factor-ÎºB, and by 17Î²-Estradiol through Sp-1 in Human Vascular Endothelial Cells. Journal of Biological Chemistry, 2000, 275, 25781-25790.	3.4	383
373	Insulin Stimulates the Growth and Tube Formation of Human Microvascular Endothelial Cells through Autocrine Vascular Endothelial Growth Factor. Microvascular Research, 1999, 57, 329-339.	2.5	61
374	Advanced Glycation Endproducts Accelerate Calcification in Microvascular Pericytes. Biochemical and Biophysical Research Communications, 1999, 258, 353-357.	2.1	103
375	Upregulation of Retinal Vascular Endothelial Growth Factor mRNAs in Spontaneously Diabetic Rats without Ophthalmoscopic Retinopathy. Ophthalmic Research, 1998, 30, 333-339.	1.9	63
376	Advanced Glycation End Products-driven Angiogenesis in Vitro. Journal of Biological Chemistry, 1997, 272, 8723-8730.	3.4	253
377	Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin-producing ability of endothelial cells through interactions with their receptors. FEBS Letters, 1996, 384, 103-106.	2.8	48
378	Advanced Glycation Endproductsâ€“Receptor Interactions Stimulate the Growth of Human Pancreatic Cancer Cells through the Induction of Platelet-Derived Growth Factor-B. Biochemical and Biophysical Research Communications, 1996, 222, 700-705.	2.1	46

#	Article	IF	Citations
379	Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and Pericytes. Journal of Biological Chemistry, 1995, 270, 28316-28324.	3.4	259